HC Wainwright Reaffirms “Buy” Rating for Oncolytics Biotech (NASDAQ:ONCY)

Oncolytics Biotech (NASDAQ:ONCY)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a report released on Thursday,Benzinga reports. They presently have a $5.00 target price on the stock. HC Wainwright’s target price would suggest a potential upside of 410.20% from the stock’s current price.

Oncolytics Biotech Stock Performance

NASDAQ:ONCY opened at $0.98 on Thursday. The stock has a 50-day simple moving average of $1.09 and a 200 day simple moving average of $1.06. Oncolytics Biotech has a 52-week low of $0.84 and a 52-week high of $1.75. The company has a market cap of $75.53 million, a PE ratio of -3.63 and a beta of 1.69.

Institutional Trading of Oncolytics Biotech

A hedge fund recently bought a new stake in Oncolytics Biotech stock. Virtu Financial LLC bought a new stake in Oncolytics Biotech Inc. (NASDAQ:ONCY) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 51,889 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned approximately 0.07% of Oncolytics Biotech at the end of the most recent quarter. 6.82% of the stock is currently owned by institutional investors and hedge funds.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.